Abstract
Despite recent advances in medical research, the incidence of diabetes and cardiovascular disease (CVD)-induced fatal events is increasing. The literature point towards several co-occurring pathways that could lead to terminal complications related with these diseases. Different pathophysiological alterations such as hyperglycaemia, hyperinsulinaemia, insulin resistance, obesity, endothelial dysfunction and oxidative stress lead to the initiation and progression of atherosclerotic plaques. In view of the continuous rise in fatal events and overlapping pathological conditions associated with CVD and diabetes, there is a critical need to develop a common treatments against these diseases. The present review highlights the possible use of common drugs that could target diabetes and associated CVD.
Keywords: Cardiovascular disease, diabetes mellitus, glycaemic imbalance, obesity, oxidative stress.
Current Vascular Pharmacology
Title:Common Therapeutic Modalities Against Diabetes and Associated Cardiovascular Disease
Volume: 15 Issue: 4
Author(s): Nasimudeen R Jabir, Chelapram Kandy Firoz, Ghulam Md Ashraf, Syed Kashif Zaidi, Shazi Shakil, Mohammad Amjad Kamal and Shams Tabrez*
Affiliation:
- King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589,Saudi Arabia
Keywords: Cardiovascular disease, diabetes mellitus, glycaemic imbalance, obesity, oxidative stress.
Abstract: Despite recent advances in medical research, the incidence of diabetes and cardiovascular disease (CVD)-induced fatal events is increasing. The literature point towards several co-occurring pathways that could lead to terminal complications related with these diseases. Different pathophysiological alterations such as hyperglycaemia, hyperinsulinaemia, insulin resistance, obesity, endothelial dysfunction and oxidative stress lead to the initiation and progression of atherosclerotic plaques. In view of the continuous rise in fatal events and overlapping pathological conditions associated with CVD and diabetes, there is a critical need to develop a common treatments against these diseases. The present review highlights the possible use of common drugs that could target diabetes and associated CVD.
Export Options
About this article
Cite this article as:
Jabir R Nasimudeen, Firoz Kandy Chelapram, Ashraf Md Ghulam, Zaidi Kashif Syed, Shakil Shazi, Kamal Amjad Mohammad and Tabrez Shams*, Common Therapeutic Modalities Against Diabetes and Associated Cardiovascular Disease, Current Vascular Pharmacology 2017; 15 (4) . https://dx.doi.org/10.2174/1570161115666170105125034
DOI https://dx.doi.org/10.2174/1570161115666170105125034 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Prevalence and Risk Factors of Gastroesophageal Reflux Disease in Hemodialysis Patients
Current Signal Transduction Therapy Statins in the Treatment of Acute Ischemic Stroke
Current Pharmaceutical Biotechnology Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk
Current Pharmaceutical Design Sepsis and Solid Organ Transplantation
Current Drug Targets Mechanisms of Dexamethasone-Induced Hypertension
Current Hypertension Reviews Beneficial Effects of Corn Silk on Metabolic Syndrome
Current Pharmaceutical Design Emerging Role of JNK in Insulin Resistance
Current Diabetes Reviews Impact of Immune Response on the Use of iPSCs in Disease Modeling
Current Stem Cell Research & Therapy Reduction of Myocardial Ischemia-Reperfusion Injury with Pre- and Postconditioning: Molecular Mechanisms and Therapeutic Targets
Cardiovascular & Hematological Disorders-Drug Targets Novel Strategies to Ameliorate Radiation Injury: A Possible Role for Tetrahydrobiopterin
Current Drug Targets Does Metformin Satisfy as an Option for Host-Directed Therapy in COVID-19?
Anti-Infective Agents In Vivo and In Vitro Evaluation of the Therapeutic Potential of Some Turkish Scorzonera Species as Wound Healing Agent
Current Pharmaceutical Design Iron Overload and Glucose Metabolism in Subjects with β-thalassaemia Major : An Overview
Current Diabetes Reviews Antiglycation Activity of N, N-Diethylthiobarbiturates Derivatives
Letters in Drug Design & Discovery Patent Selections
Recent Patents on Biomarkers Annual Trends in Use of Periconceptional Folic Acid and Birth Prevalence of Major Congenital Malformations
Current Drug Safety Endless Pursuit: Evolution of Insulin Administration
Current Pharmaceutical Biotechnology Edaravone (3-Methyl-1-Phenyl-2-Pyrazolin-5-one), A Novel Free Radical Scavenger, for Treatment of Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Therapies Targeting Innate Immunity for Fighting Inflammation in Atherosclerosis
Current Pharmaceutical Design Chemometric Assisted Simultaneous Analysis of Verapamil Hydrochloride, Gliclazide and Simvastatin in Bulk Drug and Fixed Dose Combinatinos (polypill) - A Futuristic Approach
Current Analytical Chemistry